HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenfeld, S. S. Articles by Schold, S. C. Search for Related Content PubMed PubMed Citation Articles by Rosenfeld, S. S. Articles by Schold, S. C.

Studies of Primary Central Nervous System Lymphoma with Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography

Departments of Internal Medicine (Neurology) and Radiology (Nuclear Medicine), Duke University Medical Center, Durham, North Carolina

Correspondence: For reprints contact: Steven S. Rosenfeld, MD, PhD, Department of Neurology, University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294.

ABSTRACT

Primary CNS lymphoma is a rare and highly malignant primary brain tumor. Ten patients with biopsy-proven primary CNS lymphoma were studied with ¹⁸F-2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET) to demonstrate the findings in patients with this tumor. The accumulation of FDG in primary CNS lymphoma is similar to that seen in anaplastic gliomas and is significantly more prominent than in low grade astrocytomas (p = 0.001). Steroid therapy substantially reduced the amount of FDG uptake in the one case studied both before and after its administration. The difference in FDG uptake between steroid-treated and untreated cases of primary CNS lymphoma, however, did not reach statistical significance (p = 0.40). Primary CNS lymphoma, like gliomas, suppresses the metabolism of both contiguous and distant but functionally linked areas of the brain. This study thus shows that the metabolic behavior of primary CNS lymphoma, as monitored by FDG-PET, resembles that of malignant glial tumors.

This article has been cited by other articles:

				N. Kosaka, T. Tsuchida, H. Uematsu, H. Kimura, H. Okazawa, and H. Itoh 18F-FDG PET of Common Enhancing Malignant Brain Tumors Am. J. Roentgenol., June 1, 2008; 190(6): W365 - W369. [Abstract] [Full Text] [PDF]

				S. M Selkirk and J. Shi Relapsing-remitting tumefactive multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 731 - 734. [Abstract] [PDF]